Form 8-K

0001171843-24-002550.txt : 20240506 0001171843-24-002550.hdr.sgml : 20240506 20240506070300 ACCESSION NUMBER: 0001171843-24-002550 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240506 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240506 DATE AS OF CHANGE: 20240506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000882796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 621413174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23186 FILM NUMBER: 24915508 BUSINESS ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-859-1302 MAIL ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 8-K 1 f8k_050624.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 6, 2024

_______________________________

BioCryst Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	000-23186	62-1413174
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

4505 Emperor Blvd., Suite 200

Durham, North Carolina 27703

(Address of Principal Executive Offices) (Zip Code)

(919) 859-1302

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	BCRX	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On May 6, 2024, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing recent corporate developments and its financial results for the first quarter ended March 31, 2024, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein.

The information in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

99.1		Press release dated May 6, 2024 entitled "BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update"
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BioCryst Pharmaceuticals, Inc.


Date: May 6, 2024	By:	/s/ Alane Barnes
		Alane Barnes
		Chief Legal Officer

EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million—

—Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) —

—Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials—

RESEARCH TRIANGLE PARK, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

“We are off to a fantastic start to the year with outstanding ORLADEYO revenue growth and our prioritized pipeline programs advancing on schedule. We are focused on continuing this momentum as we see strong patient demand for ORLADEYO and more pipeline programs advancing into the clinic, starting later this year,” said Jon Stonehouse, president and chief executive officer of BioCryst.

ORLADEYO^® (berotralstat): Oral, Once-daily Treatment for Prevention of Hereditary Angioedema (HAE) Attacks

ORLADEYO net revenue in the first quarter of 2024 was $88.9 million (+30 percent year-over-year (y-o-y)).
In the first quarter, the U.S. commercial team accelerated patients going through annual reimbursement reauthorization from free drug to paid drug faster than in previous years, generating higher than expected ORLADEYO revenue.
New patient growth remained strong, with the past two quarters having the most new prescriptions in the United States since the first two quarters of the launch.
Sales from outside the U.S. contributed 10 percent of global ORLADEYO net revenues in the first quarter, as the number of patients treated with ORLADEYO continued to grow strongly and consistently in new and existing markets.
New real-world evidence showing significant reductions in healthcare resource utilization among patients with HAE following ORLADEYO initiation to be presented in a poster on May 8 at the 2024 International Society for Pharmacoeconomics and Outcomes Research conference (ISPOR).

“Our team made exceptional efficiency improvements in the U.S. prescription reauthorization process, and new prescriptions remained very strong as physicians and patients increasingly understand that ORLADEYO provides excellent efficacy and convenience. These two successes helped us exceed our revenue projections for the quarter and, as a result, we are increasing our revenue guidance for 2024,” said Charlie Gayer, chief commercial officer of BioCryst.

Rare Disease Pipeline

The goal with our pipeline is to continue bringing selected, highly differentiated rare disease products to the market, and to reproduce the commercial success we have delivered with ORLADEYO. Milestones in the next 18 months include:

The ongoing proof-of-concept trial with BCX10013, an oral Factor D inhibitor, remains on track. The company expects to partner or discontinue the program later this year.
Enrollment is complete in the APeX-P pediatric trial. Data from the trial will support a regulatory filing in 2025 to expand the ORLADEYO label to enable children as young as two years of age to receive ORLADEYO. ORLADEYO would be the first oral prophylactic therapy for children with HAE.
The company expects to advance BCX17725, its KLK-5 inhibitor for the treatment of Netherton syndrome, into the clinic by the end of 2024.
- Netherton syndrome is a rare, lifelong genetic disorder that often presents in neonates or infancy with red, scaly and inflamed skin and susceptibility to recurrent skin infections. Netherton syndrome can be life threatening, especially during infancy when patients are vulnerable to dehydration and recurrent infections. Currently, there is no approved treatment for Netherton syndrome.
In 2025, the company plans to advance avoralstat, a plasma kallikrein inhibitor, into a clinical trial of patients with diabetic macular edema (DME).
- DME is the most common cause of vision loss in individuals with diabetes and at least one-third of patients have persistent DME despite anti-VEGF therapies, which are administered via monthly injection. By delivering avoralstat with Clearside’s SCS microinjector^® directly into the suprachoroidal space of the eye in the clinical trial, avoralstat could inhibit plasma kallikrein at the sites of edema formation in DME disease, the retinal and choroidal vascular endothelium. With its low solubility, the drug could persist in the eye at the site of disease for a long duration, resulting in less frequent injections.

“It is very exciting to be advancing our pipeline of first-in-class/best-in-class molecules into the clinic to generate proof-of-concept data across multiple programs and diseases, and to be so close to delivering the first oral prophylactic option to children with HAE,” said Dr. Helen Thackray, chief research and development officer of BioCryst.

First Quarter 2024 Financial Results

For the three months ended March 31, 2024, total revenues were $92.8 million, compared to $68.8 million in the first quarter of 2023 (+34.9 percent y-o-y). The increase was primarily due to $88.9 million in ORLADEYO net revenue in the first quarter of 2024, compared to $68.4 million in ORLADEYO net revenue in the first quarter of 2023 (+30 percent y-o-y).

Research and development (R&D) expenses for the first quarter of 2024 decreased to $46.5 million from $48.4 million in the first quarter of 2023 (-3.9 percent y-o-y), primarily due to decreased spending on BCX10013 due to our plan to either out-license or discontinue late-stage development and commercialization, which was announced in January 2024, as well as the discontinuation of the BCX9930 program, which was announced in December 2022. These reductions were partially offset by increased investment in BCX17725 and other discovery programs, and ORLADEYO label expansion and life cycle investments, such as our ongoing ORLADEYO pediatric trial.

Selling, general and administrative (SG&A) expenses for the first quarter of 2024 increased to $59.4 million, compared to $47.9 million in the first quarter of 2023 (+24.0 percent y-o-y). The increase was primarily due to increased investment to expand and enhance the U.S. commercial team and expand and support international operations.

Operating loss for the first quarter was $14.5 million, adjusted to $0.8 million excluding non-cash stock compensation.

Interest expense was $24.5 million in the first quarter of 2024, compared to $27.4 million in the first quarter of 2023 (-10.6 percent y-o-y). The decrease was primarily due to a decrease in the amortization of interest associated with our royalty financing obligations, partially offset by an increase in interest expense associated with the Pharmakon debt refinancing secured in April 2023.

Net loss for the first quarter of 2024 was $35.4 million, or $0.17 per share, compared to a net loss of $53.3 million, or $0.28 per share, for the first quarter of 2023. Non-GAAP net loss for the first quarter of 2024 was $34.1 million, or $0.17 per share when excluding one-time costs associated with the R&D restructuring, totaling $1.3 million. A reconciliation between GAAP and non-GAAP net loss is provided in the table below.

Cash, cash equivalents, restricted cash and investments totaled $338.4 million at March 31, 2024, compared to $403.1 million at March 31, 2023. Net cash utilization for the first quarter of 2024 was $52.4 million, which was driven by debt service, royalty payments and one-time first quarter compensation expense. We expect, as in previous years, that the first quarter will be the highest quarter of operating cash use for the year, and that operating cash use for the remaining quarters of 2024 will normalize around $10-$12 million per quarter. We expect that total cash at the end of 2024 will be above $300 million.

Non-GAAP Pro forma Financial Measures

The information furnished in this release includes non-GAAP pro forma financial measures that differ from measures calculated in accordance with generally accepted accounting principles in the United States of America (“GAAP”), including financial measures labeled as “non-GAAP” or “adjusted.”

We believe providing these non-GAAP measures, which show our pro forma results with these items adjusted, is valuable and useful since they allow the company and investors to better understand the company’s financial performance in the absence of these one-time events and allowed investors to more accurately understand our current period results and more easily compare them to future results. These non-GAAP pro forma measures also correspond with the way we expect investors and financial analysts to compare our results. Our non-GAAP pro forma measures should be considered only as supplements to, and not as substitutes for or in isolation from, our other measures of financial information prepared in accordance with GAAP, such as GAAP revenue, operating income, net income, and earnings per share.

Our references to our first quarter 2024 “non-GAAP pro forma” financial measures of adjusted net loss and adjusted earnings per share constitute non-GAAP financial measures. They refer to our GAAP results, adjusted to show the results without the one-time costs associated with the R&D restructuring. A reconciliation between GAAP and non-GAAP net loss is provided in the table below.

Financial Outlook for 2024

Based on the team’s success in accelerating ORLADEYO patients through the U.S. reauthorization process faster than anticipated, the company is adjusting its outlook for full year 2024 global net ORLADEYO revenue to be between $390 million and $400 million, the top end of its prior guidance range.

The company expects full year 2024 operating expenses to be between $365 million and $375 million, flat to full year 2023 operating expenses.

This operating expense outlook does not reflect non-cash stock compensation expense, or one-time expenses related to the previously announced workforce reduction implemented in the first quarter of 2024.

Based on the company’s disciplined approach to capital allocation, and the adjusted revenue guidance for ORLADEYO, the company is even more confident that it will achieve a full-year operating profit in 2024 (not including non-cash stock compensation), be approaching quarterly positive earnings per share (EPS) and positive cash flow in the second half of 2025 (not including non-cash stock compensation), and be profitable on an EPS basis, with positive cash flow, for full year 2026. The company expects it can achieve these financial milestones without raising additional funds and does not intend to draw the additional $150 million of debt available to it from Pharmakon.

Conference Call and Webcast
BioCryst management will host a conference call and webcast at 8:30 a.m. ET today to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO^® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst’s ability to successfully implement its commercialization plans for ORLADEYO, which could take longer or be more expensive than planned; BioCryst’s ability to successfully implement its plans for BCX10013, including that the results of the ongoing proof-of-concept trial may differ from BioCryst’s expectations and that BioCryst may not be able to successfully out-license the late-stage development and commercialization of BCX10013; BioCryst’s ability to successfully progress its pipeline development plans as described herein; risks related to the reduction in size of BioCryst’s R&D organization; the results of BioCryst’s partnerships with third parties may not meet BioCryst’s current expectations; risks related to government actions, including that decisions and other actions, including as they relate to pricing, may not be taken when expected or at all, or that the outcomes of such decisions and other actions may not be in line with BioCryst’s current expectations; the commercial viability of ORLADEYO, including its ability to achieve market acceptance; ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; product candidates, if approved, may not achieve market acceptance; BioCryst’s ability to successfully commercialize its products and product candidates; BioCryst’s ability to successfully manage its growth and compete effectively; risks related to the international expansion of BioCryst’s business; timing for achieving profitability and positive cash flow may not meet management’s expectations; statements and projections regarding financial guidance and goals and the attainment of such goals may differ from actual results based on market factors and BioCryst’s ability to execute its operational and budget plans; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management's expected ranges. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

BIOCRYST PHARMACEUTICALS, INC.
CONSOLIDATED FINANCIAL SUMMARY
(In thousands, except per share)

Statements of Operations (unaudited)

	Three Months Ended March 31,
		2024			2023
Revenues:
ORLADEYO	$	88,867		$	68,414
Other		3,894			364
Total revenues		92,761			68,778

Expenses:
Cost of product sales		1,265			931
Research and development		46,493			48,388
Selling, general and administrative		59,364			47,867
Royalty		127			7
Total operating expenses		107,249			97,193

Loss from operations		(14,488	)		(28,415	)

Interest income		4,031			3,378
Interest expense		(24,506	)		(27,396	)
Foreign currency losses, net		(51	)		(229	)
Loss before income taxes	$	(35,014	)	$	(52,662	)
Income tax expense		365			671
Net loss	$	(35,379	)	$	(53,333	)

Basic and diluted net loss per common share	$	(0.17	)	$	(0.28	)

Weighted average shares outstanding		206,064			188,509

Balance Sheet Data (in thousands)

	March 31, 2023 (unaudited)			December 31, 2023 (Note 1)
Cash, cash equivalents and investments	$	336,554		$	388,987
Restricted cash		1,798			1,804
Receivables		60,586			56,950
Total assets		467,892			516,960
Secured term loan		308,484			303,231
Royalty financing obligation		530,574			531,599
Accumulated deficit		(1,716,538	)		(1,681,159	)
Stockholders’ deficit		(476,167	)		(455,528	)
Shares of common stock outstanding		206,347			205,771

Note 1: Derived from audited financial statements.

Reconciliation of Adjusted Net Loss and Adjusted Diluted Earnings Per Share (in thousands)

	Three Months Ended March 31,
		2024			2023
GAAP net loss	$	(35,379	)	$	(53,333	)
Less: One-time R&D restructuring expense		(1,264	)		—
Adjusted net loss	$	(34,115	)	$	(53,333	)

GAAP basic and diluted net loss per common share	$	(0.17	)	$	(0.28	)

Adjusted basic and diluted net loss per common share	$	(0.17	)	$	(0.28	)

EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	May 06, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	May 06, 2024
Entity File Number	000-23186
Entity Registrant Name	BioCryst Pharmaceuticals, Inc.
Entity Central Index Key	0000882796
Entity Tax Identification Number	62-1413174
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	4505 Emperor Blvd., Suite 200
Entity Address, City or Town	Durham
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	27703
City Area Code	919
Local Phone Number	859-1302
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	BCRX
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 / / v2.2.0.24 / / DefRef Styles / ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } / Report Styles / ..pl a, .pl a:visited { color: black; text-decoration: none; } / table / ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } / Top labels / ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; / word-wrap: break-word; / } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } / Header rows... / ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } / Calendars... / ..report .rc { background-color: #f0f0f0; } / Even rows... / ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } / Odd rows... / ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } / styles for footnote marker / ..report .fn { white-space: nowrap; } / styles for numeric types / ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } / styles for text types / ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_050624.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "f8k_050624.htm": { "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "dts": { "inline": { "local": [ "f8k_050624.htm" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://globenewswire.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_050624.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_050624.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001171843-24-002550-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-24-002550-xbrl.zip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f8k_050624_htm.xml IDEA: XBRL DOCUMENT 0000882796 2024-05-06 2024-05-06 iso4217:USD shares iso4217:USD shares 0000882796 false 8-K 2024-05-06 BioCryst Pharmaceuticals, Inc. DE 000-23186 62-1413174 4505 Emperor Blvd., Suite 200 Durham NC 27703 919 859-1302 false false false false Common Stock BCRX NASDAQ false